IMVT Earnings

Quarterly EPS
$-0.74
Q2 2025
$-0.76
Q3 2025
$-0.64
Q4 2025
$-0.71
Q1 2026
$-0.73
Q2 2026
$-0.61
Q3 2026
$-0.73
Q4 2026
$-0.75
Q1 2027
Latest RevenueN/A
Latest Net Income-153224000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q1 2027-$0.750-153224000—-5.6%
Q4 2026-$0.730-147856000—-14.1%
Q3 2026-$0.610-110635000—+19.7%
Q2 2026-$0.730-126502000—+1.4%
Q1 2026-$0.710-120613000—-18.3%
Q4 2025-$0.640-106449000—-23.1%
Q3 2025-$0.760-111122000—-111.1%
Q2 2025-$0.740-109119000—-64.4%
Q1 2025-$0.600-87150000——
Q4 2024-$0.520-75319000——
Q3 2024-$0.360-51418000——
Q2 2024-$0.450-58662000——
Immunovant (IMVT) — Earnings